Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report

Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐sensitive mutations. However, the response of patients with rare...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Kunyan, Nie, Ligong, Nong, Lin, Cheng, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201540/
https://www.ncbi.nlm.nih.gov/pubmed/33960639
http://dx.doi.org/10.1111/1759-7714.13983
_version_ 1783707833736364032
author Sun, Kunyan
Nie, Ligong
Nong, Lin
Cheng, Yuan
author_facet Sun, Kunyan
Nie, Ligong
Nong, Lin
Cheng, Yuan
author_sort Sun, Kunyan
collection PubMed
description Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐sensitive mutations. However, the response of patients with rare ALK rearrangements to tyrosine kinase inhibitors remains unknown. Here, we report a rare case of striatin (STRN)‐ALK‐positive NSCLC showing primary resistance to first‐line therapy alectinib and limited clinical activity of crizotinib in the alectinib‐resistant setting.
format Online
Article
Text
id pubmed-8201540
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-82015402021-06-16 Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report Sun, Kunyan Nie, Ligong Nong, Lin Cheng, Yuan Thorac Cancer Case Reports Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐sensitive mutations. However, the response of patients with rare ALK rearrangements to tyrosine kinase inhibitors remains unknown. Here, we report a rare case of striatin (STRN)‐ALK‐positive NSCLC showing primary resistance to first‐line therapy alectinib and limited clinical activity of crizotinib in the alectinib‐resistant setting. John Wiley & Sons Australia, Ltd 2021-05-07 2021-06 /pmc/articles/PMC8201540/ /pubmed/33960639 http://dx.doi.org/10.1111/1759-7714.13983 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Sun, Kunyan
Nie, Ligong
Nong, Lin
Cheng, Yuan
Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
title Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
title_full Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
title_fullStr Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
title_full_unstemmed Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
title_short Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
title_sort primary resistance to alectinib in a patient with strn‐alk‐positive non‐small cell lung cancer: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201540/
https://www.ncbi.nlm.nih.gov/pubmed/33960639
http://dx.doi.org/10.1111/1759-7714.13983
work_keys_str_mv AT sunkunyan primaryresistancetoalectinibinapatientwithstrnalkpositivenonsmallcelllungcanceracasereport
AT nieligong primaryresistancetoalectinibinapatientwithstrnalkpositivenonsmallcelllungcanceracasereport
AT nonglin primaryresistancetoalectinibinapatientwithstrnalkpositivenonsmallcelllungcanceracasereport
AT chengyuan primaryresistancetoalectinibinapatientwithstrnalkpositivenonsmallcelllungcanceracasereport

Ejemplares similares